Massive Epigenetic Study Reveals Why Parkinson’s Disease Strikes Men and Women Differently

Parkinson’s disease has long been known to behave differently in men and women. Women are diagnosed less often, tend to develop the disorder later in life, and frequently experience a different constellation of symptoms and progression patterns than men. Yet the biological roots of these sex differences have remained stubbornly obscure, buried somewhere in the interplay between hormones, genetics, and environment. Now, a large-scale epigenetic study published in npj Parkinson’s Disease has mapped, in unprecedented detail, how the chemical tags that regulate gene activity differ between male and female patients, offering the most comprehensive resource to date for understanding the sex-specific biology of the disease.

The research, led by Tianmi Yang and colleagues at West China Hospital of Sichuan University, took aim at DNA methylation, one of the most studied mechanisms of epigenetic regulation. Methylation involves the attachment of small chemical groups called methyl groups to specific positions along the DNA molecule, most commonly at cytosine bases. These tags do not change the underlying genetic sequence, but they act like volume knobs on genes, dialing their activity up or down. Because methylation patterns can shift in response to disease processes and can differ between the sexes, comparing methylation profiles between male and female patients offers a window into molecular differences that conventional genetic studies cannot capture.

To achieve the statistical power needed for such a comparison, the team designed a two-stage study. In the discovery stage, they analyzed blood samples from 1,143 patients with Parkinson’s disease and 1,013 matched healthy controls drawn from two independent datasets. Rather than analyzing each dataset separately and risking spurious findings, the researchers performed an epigenome-wide meta-analysis, a technique that combines the statistical evidence from multiple cohorts while accounting for their individual quirks. This approach allowed them to systematically scan hundreds of thousands of methylation positions across the genome and identify sites where the methylation difference between patients and controls itself differed between males and females.

The results were striking. The analysis identified 2,199 positions, known as sex-differentially methylated positions, that showed sex-specific methylation changes unique to Parkinson’s disease, along with 365 larger stretches of DNA, called sex-differentially methylated regions, with the same property. A consistent directional pattern emerged: across these disease-specific loci, males generally showed lower methylation levels than females. Because reduced methylation at certain genomic features is often associated with increased gene activity, this pattern hints that male and female patients may be running different transcriptional programs in the cells that carry these marks, although the authors caution that methylation differences in blood do not translate directly into gene expression changes in the brain.

To understand what these methylation differences might mean biologically, the team annotated the flagged loci to nearby genes and ran enrichment analyses, which test whether particular functional categories of genes appear more often than chance would predict. The genes linked to the sex-differential methylation signals were significantly enriched in neurodevelopmental and synaptic processes, the very machinery involved in building and maintaining the connections between neurons that degenerate in Parkinson’s disease. Among the annotated genes, network analysis highlighted several candidate hub genes, central nodes in the interaction network that may exert outsized influence: PINK1, a kinase famous for its role in mitochondrial quality control and inherited Parkinson’s disease; BCL2, a key regulator of programmed cell death; and MAPK1, a signaling molecule that relays stress and growth signals within cells. Each of these genes sits squarely within pathways already implicated in the death of dopamine-producing neurons, lending biological plausibility to the methylation signals.

A major weakness of many epigenome-wide association studies is that they capture only a single snapshot in time, leaving open the question of whether the observed patterns are stable features of the disease or transient fluctuations. The team addressed this by turning to the Parkinson’s Progression Markers Initiative cohort, a rich longitudinal resource. In the validation stage, they integrated DNA methylation measurements taken at multiple time points with transcriptomic data and clinical assessments, testing whether the sex-differential methylation patterns held up as the disease progressed. The longitudinal data supported the relative stability of these sex-specific methylation signatures over time, suggesting they are not merely noise or a fleeting response to early diagnosis but potentially durable molecular features of how Parkinson’s disease unfolds differently in each sex.

The researchers also confronted the perennial problem of tissue relevance. DNA methylation is tissue-specific, and the study relied on blood samples, which are far easier to collect than brain tissue but may not reflect methylation in the neurons that actually degenerate. To probe this, the team used saliva samples to check cross-tissue consistency of the signals and performed in silico analyses comparing blood methylation data with methylation maps derived from brain tissue. Concordance across these sources strengthens the argument that at least some of the sex-differential signals are not artifacts of blood cell composition but may mirror processes relevant to the central nervous system. Still, the authors are explicit that blood-based findings remain an indirect readout, and that bridging the gap between peripheral methylation and brain biology will require further work.

The scale and rigor of the study owe much to the cohorts that fed it. The discovery datasets included contributions from the SGPD cohort, encompassing samples from the Queensland Parkinson’s Project in Australia and the New Zealand Brain Research Institute, as well as the PEG studies funded by the United States National Institute of Environmental Health Sciences to investigate environmental exposure, DNA methylation, and Parkinson’s disease. The longitudinal validation drew on the Parkinson’s Progression Markers Initiative, a public-private partnership funded by The Michael J. Fox Foundation for Parkinson’s Research and a long list of industry partners. The analysis itself was supported by the National Natural Science Foundation of China and the Science and Technology Bureau Fund of Sichuan Province, with additional support from the Chengdu Scientific Research Fund.

Why does this matter for patients? Sex-aware medicine is one of the fastest-growing frontiers in neurology, and Parkinson’s disease is a prime candidate for it. Women with Parkinson’s are underrepresented in many clinical trials, and treatment responses, side effect profiles, and disease trajectories differ between the sexes in ways that standard models ignore. A validated catalog of sex-differential methylation sites could eventually seed the development of biomarkers that stratify patients by sex, helping clinicians predict progression, tailor therapies, and monitor response more precisely. The authors position their findings as exactly that: a candidate resource for future sex-aware biomarker and mechanistic studies, not a finished clinical tool.

Indeed, the study’s own framing is refreshingly careful. The authors emphasize that prospective clinical validation and functional experiments are required before any translational application. Methylation associations do not by themselves prove causation, and the hub genes identified through network analysis remain candidates rather than confirmed drivers. Follow-up experiments in cellular models, ideally in sex-specific contexts, will be needed to test whether the methylation differences at loci such as PINK1, BCL2, and MAPK1 influence neuronal survival, mitochondrial function, or inflammatory signaling. If they do, the epigenetic differences documented here could point toward mechanisms that explain why men and women experience Parkinson’s disease so differently, and perhaps toward interventions that close the gap. For now, the study stands as a landmark map, drawn at epigenome-wide resolution, of a dimension of Parkinson’s disease that medicine has long observed but only now begun to chart at the molecular level.

Subject of Research: Sex-differential DNA methylation signatures in Parkinson's disease identified through epigenome-wide meta-analysis

Article Title: Epigenome-wide meta-analysis of sex-differential DNA methylation in Parkinson’s disease

Article References: Yang, T., Li, C., Wei, Q., Pang, D., Ou, R., Zhang, L., Cheng, Y., Huang, J., Lin, J., Che, N., Xiao, Y., Fu, J., Jiang, Q., Wang, S., Zheng, X., Yang, Y., Chen, Y., Yu, H., & Shang, H. (2026). Epigenome-wide meta-analysis of sex-differential DNA methylation in Parkinson’s disease. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01582-7

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01582-7

Keywords: Parkinson's disease, DNA methylation, epigenetics, sex differences, meta-analysis, biomarkers, PINK1, BCL2, MAPK1, neurodegeneration, longitudinal study, gene expression